Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative Medicine
Oncocross, a Seoul-based artificial intelligence (AI) drug discovery and development biotech startup, has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform.
JW Pharmaceutical has begun marketing Livalozet, the first domestic combination drug of pitavastatin and ezetimibe, for treating dyslipidemia.
JW Pharmaceutical said Wednesday it has applied to patent its anti-cancer pipeline CWP291 as a potential COVID-19 treatment.
South Korea’s JW Pharmaceutical has started targeting emerging markets with a deal for a plant in Vietnam.
Korea--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, and Korean JW Pharmaceutical today announced that LEO Pharma has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a pharmacokinetics study in the US.
JW Pharmaceutical will receive upfront and milestone payments of up to USD 402 million. Apart from such milestone payments, a royalty will be awarded.